Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic a...

por Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Publicado 2016

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients...

por Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
Publicado 2016

NOX1 loss-of-function genetic variants in patients with inflammatory bowel disease

por Schwerd, T., Bryant, R. V., Pandey, S., Capitani, M., Meran, L., Cazier, J.-B., Jung, J., Mondal, K., Parkes, M., Mathew, CG, Fiedler, K., McCarthy, D. J., Sullivan, PB, Rodrigues, A., Travis, SPL, Moore, C., Sambrook, J., Ouwehand, W. H., Roberts, D. J., Danesh, J., Russell, R. K., Wilson, D. C., Kelsen, J. R., Cornall, R., Denson, L. A., Kugathasan, S., Knaus, U. G., Goncalves Serra, E., Anderson, C. A., Duerr, R. H., McGovern, D. P. B., Cho, J., Powrie, F., Li, V. S. W., Muise, A. M., Uhlig, H. H.
Publicado 2017